Merck Says R&D Efficiency Is Above Average, Rx Prices Not Tied To Research

The increasing cost of drug development will force companies to compete based on the efficiency of their R&D programs, Merck CEO Raymond Gilmartin suggested during a Nov. 30 Tufts Center for the Study of Drug Development briefing in Philadelphia

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet